FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study.
Michal EiferHodaya PinianEyal KlangYousef AlhoubaniNayroz KananaNoam TauTima DavidsonEli KonenOnofrio A CatalanoYael EshetLiran DomachevskyPublished in: European radiology (2022)
• Patients who were vaccinated with the COVID-19 mRNA vaccine have shown FDG-avid reactive axillary lymph nodes in PET-CT scans. • We evaluated if radiomics and machine learning can distinguish between FDG-avid metastatic axillary lymphadenopathy in breast cancer patients and FDG-avid reactive axillary lymph nodes. • Combined PET and CT radiomics data showed good test AUC (0.98) for distinguishing between metastatic axillary lymphadenopathy and post-COVID-19 vaccine-associated axillary lymphadenopathy. Therefore, the use of radiomics may have a role in differentiating between benign from malignant FDG-avid nodes.
Keyphrases
- lymph node
- pet ct
- sentinel lymph node
- positron emission tomography
- neoadjuvant chemotherapy
- contrast enhanced
- coronavirus disease
- sars cov
- computed tomography
- pet imaging
- ultrasound guided
- machine learning
- fine needle aspiration
- lymph node metastasis
- small cell lung cancer
- metastatic breast cancer
- magnetic resonance imaging
- big data
- respiratory syndrome coronavirus
- radiation therapy
- locally advanced
- rectal cancer